MedTrace Logo

Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia

NCT04793919 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 89

Last updated 2024-04-15

No results posted yet for this study

Summary

The trial is open to all patients with a diagnosis of acute promyelocytic leukemia (APL) who are PCR-positive for the PML-RARα transcript and less than 18 years of age.

Conditions

  • Acute Promyelocytic Leukemia

Interventions

DRUG

Mylotarg

See the protocol

DRUG

Arsenic Trioxide

See the protocol

DRUG

All-trans retinoic acid

See the protocol

Sponsors & Collaborators

  • Associazione Italiana Ematologia Oncologia Pediatrica

    lead OTHER

Principal Investigators

  • Fanco Locatelli, Prof · Dept. of Pediatric Hematology Oncology - Bambino Gesù Children's Hospital Rome

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-09
Primary Completion
2025-10-09
Completion
2027-10-10

Countries

  • Belgium
  • Czechia
  • Denmark
  • France
  • Germany
  • Ireland
  • Israel
  • Italy
  • Netherlands
  • Portugal
  • Spain
  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04793919 on ClinicalTrials.gov